Dr G Thomas Budd presents data on a phase III randomised clinical trial that found low-dose weekly administration of paclitaxel and standard dose, every two weeks administration, resulted in equal progression-free survival for women with higher-risk early-stage breast cancer who have undergone surgery.

However, researchers found that certain side effects were more common with the every two weeks regimen, suggesting the weekly schedule may be preferable.

Visit ecancerNews to read more